New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (G ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Tuesday.The Dow traded down 0.22% to 48,353.51 while the NASDAQ slipped 0.16% to 23,436.70. The S&P 500 also fell, dropping, 0.13% to 6,896.56.Check This Out: AAR Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate AnalystsLeading and Lagging SectorsEnergy shares rose by 0.6% on Tuesday.In trading on Tuesday, consumer discretionary stocks fell by 0.3%.Top Headlin ...

Core Insights - Autonomix Medical, Inc. has been granted a new European patent (EP4230133) that enhances its strategic position in the nerve-sensing and modulation market, which is valued in the multi-billion-dollar range [1][2] - The patent covers systems and methods for precise treatment of cardiac tissues, including feedback-driven neuromodulation and denervation, which could transform treatment in cardiology and related fields [1][2] Company Overview - Autonomix is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, with a first-in-class platform that includes a catheter-based microchip sensing array [4] - The company aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, which could significantly improve patient outcomes [4] Technology and Applications - The newly granted patent expands the company's ability to provide precision nerve-targeted therapies for conditions such as hypertension, arrhythmia management, heart failure, and refractory angina [2][3] - Autonomix's technology platform has the potential to address multiple therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [3][5] Market Potential - The patent positions Autonomix to capitalize on high-growth areas in cardiology, potentially reducing complications associated with traditional systemic treatments [2] - The company is initially developing its technology for pain management, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [5]

Core Insights - Autonomix Medical, Inc. is focused on advancing precision nerve-targeted treatments and has recently participated in a Virtual Investor CEO Connect segment [2][3] - The CEO, Brad Hauser, highlighted two main priorities: strengthening intellectual property protection and exploring applications beyond pancreatic cancer, including cardiovascular, pulmonary, and interventional pain management [3] Company Overview - Autonomix is a medical device company that aims to revolutionize the diagnosis and treatment of diseases involving the nervous system through innovative technologies [4] - The company's platform technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - Initial development efforts are focused on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [5] Technology and Applications - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [5] - The platform is still investigational and has not yet received marketing clearance in the United States [5]

THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA. Details of the poster presentation are as follows: Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of ...

Core Insights - Autonomix Medical, Inc. is focusing on advancing precision nerve-targeted treatments and has published a CEO Corner segment discussing its strategic direction [1] - The company aims to protect its platform's strength through intellectual property and is exploring new opportunities beyond pancreatic cancer into cardiovascular, pulmonary, and chronic pain areas [1] Company Overview - Autonomix is a medical device company dedicated to innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - This technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases across the body [3] Current Development Focus - The initial development of the technology is targeted at pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [4] - The technology serves as a platform for addressing multiple indications, including cardiology, hypertension, and chronic pain management [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4]

Core Insights - Autonomix Medical, Inc. announced significant improvements in quality of life for patients with severe pancreatic cancer pain following a targeted ablation therapy, as evidenced by a post-hoc exploratory subgroup analysis of its proof-of-concept study [1][4][5] Study Findings - The analysis utilized the EORTC QLQ-C30 scale to assess quality of life, symptom burden, and functionality across various patient subgroups, including those with different tumor stages and metastatic statuses [1][4] - Late-stage patients demonstrated substantial improvements, indicating that the ablation therapy provided clinically meaningful changes even in advanced disease [1][4] - Average symptom scores improved by 14.53 points at 4–6 weeks and 26.07 points at 3 months, with functionality and global quality of life also showing significant enhancements [7][10] - Patients with Stage 4 pancreatic cancer experienced a 32.48 point improvement in symptoms and an 11.85 point functional gain by 4–6 weeks, with sustained benefits at 3 months [7][10] Clinical Trial Insights - The findings will inform the design and patient selection for Autonomix's upcoming U.S.-based multicenter clinical study, set to begin in 2026, which will formally evaluate pain relief and quality-of-life outcomes [2][6] - The initial proof-of-concept study enrolled 20 patients, with 100% of responding patients achieving opioid-free status at 3 months post-procedure [10][17] Future Directions - Based on the positive results from the proof-of-concept study, Autonomix is expanding its research to include additional visceral cancers and earlier-stage pancreatic cancers, aiming to address a broader market for interventional cancer pain management [11][12]

Core Insights - Autonomix Medical, Inc. will present at the TCT 2025 Annual Scientific Conference, showcasing its innovative nerve-targeted treatment technology [1][2] - The presentations will focus on the initial phase results of a clinical study aimed at alleviating pain in pancreatic cancer patients through transvascular energy delivery [2] Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [4] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with high sensitivity [4][5] - Initial development efforts are concentrated on pain management, particularly for pancreatic cancer, which currently lacks effective treatment options [5] Conference Details - TCT 2025 is a four-day educational conference focused on interventional cardiovascular medicine, taking place from October 25-28, 2025, in San Francisco [3] - The conference is organized by the Cardiovascular Research Foundation and has grown significantly since its inception in 1988, now attracting thousands of attendees [3]

Core Insights - Autonomix Medical, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, showcasing its commitment to advancing precision nerve-targeted treatments [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [4] Technology Development - Initial development of the technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]

Core Insights - Autonomix Medical, Inc. has received a new patent that enhances its position in a multi-billion-dollar market for nerve-targeted treatments, particularly in cardiology and related fields [1][2][3] Intellectual Property Development - The company has over 120 issued and pending patent applications, indicating a strong commitment to building a comprehensive global intellectual property portfolio in nerve-sensing and modulation [1] - The newly issued U.S. Patent No. 12,369,852 covers systems and methods for sensing autonomic signals and delivering precise cardiac therapies [1][3] Market Opportunity - The patent positions Autonomix to capitalize on high-growth areas in cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina [2][3] - The technology aims to provide precision therapies that could reduce the reliance on systemic beta-blockers, which often have undesirable side effects [2][3] Technological Advancements - Autonomix's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5] - The platform has the potential to address various indications across multiple therapeutic areas, including cardiology, hypertension, and chronic pain management [4][6] Initial Focus and Future Potential - The company is initially developing its technology for pain management, specifically targeting pancreatic cancer, which is known for causing severe pain [6] - The investigational nature of the technology indicates that it has not yet received marketing clearance in the United States, suggesting ongoing development and potential future applications [6]